Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.
In this final video part of a three-part video interview series, Brian Anderson, MBA, principal and consulting actuary at Milliman, told MHE he sees a more complex picture when it comes to consolidation in the pharmacy benefit manager industry—one that still holds potential for innovation and improvement. Anderson is one of this year's six inaugural winners of Managed Healthcare Executive’s PBMI Innovator Award.
In this second part of a three-part video interview series, Brian Anderson, MBA, a principal and consulting actuary at Milliman, shared his belief that PBM transparency is essential—but he sees risks in how it's being pursued. Anderson is one of this year's six inaugural winners of Managed Healthcare Executive’s PBMI Innovator Award.
In a video interview with MHE editors, David Blair, founder, chairman, and CEO of LucyRx, expressed his belief that pharmacists are an underused resource in the U.S. healthcare system, especially at a time when access to primary care is becoming more limited. Blair is one of this year's six inaugural winners of Managed Healthcare Executive’s PBMI Innovator Award.
In a video interview with MHE editors, Brian Anderson, MBA, a principal and consulting actuary at Milliman, shared his entry into the pharmacy benefits space was driven by a desire to improve healthcare by making it easier for people to access what they need—especially medications. Anderson is one of this year's six inaugural winners of Managed Healthcare Executive’s PBMI Innovator Award.
Principal and consulting actuary, Milliman
The authors of an opinion piece in The Lancet Psychiatry make a case for paying more attention to the autistic features of schizophrenia.
Step therapy by Medicare Advantage plans was also associated with more injections, although that result fell short of meeting statistical significance standards.
Data from week 156 are favorable and no new safety signals emerged, says researcher.
Fluid resolution at week 4 seems to translate into longer dosing intervals at week 96 of the PULSAR trial that assessed Eylea HD in patients with neovascular (wet) age-related macular degeneration.
Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.
Extension study results suggest dosing intervals of 20 weeks or more for Eylea HD for diabetic macular edema.
New insights emerge from ongoing analyses of GA studies, enhancing AMD treatment strategies and patient management at Bay Area Retina Associates.
Discover new safety insights on Syfovre for geographic atrophy treatment, as Roger A. Goldberg highlights promising long-term data at ASRS 2025.
New findings reveal Syfovre may protect central vision in macular degeneration patients, delaying vision loss and enhancing treatment strategies.
New findings reveal that early treatment with Syfovre significantly improves vision preservation in geographic atrophy patients, according to Robert Goldberg, M.D., MBA, of the Bay Area Retina Associates.
Cigna has sold its Medicare businesses and slashed the number of people it covers in its ACA plans by more than half.
Interest in surgical advancements such as retinal detachment repair is driven by the need for balance within the field and a new generation entering the workforce, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
A session on a surgery technique to treat macular holes using amniotic membrane transplants will be one of the highlights at the 2025 meeting of the American Society of Retina Specialists, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
There will be a greater focus on surgical topics at the 2025 meeting of the American Society of Retina Specialists, compared with previous years, which reflects the need for balance within the industry, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
Surveys of American Society of Retina Specialists members have revealed a preference for physicians’ experiences with new therapies, rather than summaries of clinical trial data, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
The company's strong performance is due in part to increased revenue fro, pharmacy benefit services business.
Company officials say they are focusing on "more disciplined managed products" as they prepare to exit PPOs in 2026 that currently cover 800,000 members, including 600,000 people enrolled in Medicare Advantage plans.
The healthcare conglomerate says rising medical costs are squeezing earnings from operations.
Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s National Department of Health, who spoke with editors at IAS 2025 in Kigali, Rwanda.
A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope for curbing the number of new infections.
A larger role for China, perhaps, and the fraught issue of integrating HIV services into services for other diseases.
Experts, such as Lloyd Mulenga, M.Sc., M.B., Ch.B., Ph.D., discuss long-acting injectable HIV PrEP's potential in Zambia, emphasizing community involvement and sustainable rollout amid funding challenges.
The use of preexposure prophylaxis lags far behind a 2025 target of 21.2 million people.
Alarice Marsh, M.P.H., a deputy director in the National Department of Health of South Africa and program lead of HIV testing services, spoke with MHE editors about her thoughts on the new recommendations for HIV and sexually transmitted diseases that were issued by the World Health Organization (WHO) today.
